Extracted from this filing and checked against the source text.
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
Alzamend Neuro, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).
- Exchange
- nasdaq
- Notice
- deficiency notice
- Deficiency
- market value
- Rules
- 5550(b)(2)
Exact text from the filing
iled with the Securities and Exchange Commission (the “ SEC ”), which will remove the Common Stock from listing and registration on Nasdaq. The Company will request an appeal of the Staff’s determination to a Hearings Panel (the “ Panel ”), pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series, which is required to be submitted electronically no later than April 2, 2024. The hearing request will stay the suspension of the Common Stock and the filing of the Form 25-NSE pending the Panel’s decision, and the Common Stock will continue to trade on the Nasdaq Capital Market un
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Alzamend Neuro, Inc. entered into Agreement with Ault Lending, LLC valued at purchase price of $2.0 million (effective 2024-01-31).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Ault Lending, LLC
- Value
- purchase price of $2.0 million
- Effective
- 2024-01-31
Exact text from the filing
On March 26, 2024, Alzamend Neuro, Inc., a Delaware corporation (the “ Company ”), pursuant to the Securities Purchase Agreement (the “ Agreement ”) entered into with Ault Lending, LLC, a California limited liability company (the “ Purchaser ”) on January 31, 2024
View on SEC.gov